A New Inhibitor Targeting Signal Transducer and Activator of. Transcription 5 (STAT5) Signaling in Myeloid Leukemias

Transcription

1 Supporting Information A New Inhibitor Targeting Signal Transducer and Activator of Transcription 5 (STAT5) Signaling in Myeloid Leukemias Ludovic Juen,,# Marie Brachet-Botineau,,,# Cécile Parmenon, Jérôme Bourgeais,, Olivier Hérault,, Fabrice Gouilleux,*, Marie- Claude Viaud-Massuard and Gildas Prié*, Equipe IMT "Innovation Moléculaire et Thérapeutique" - GICC UMR 7292 CNRS - Université de Tours - Labex SYNORG - Faculté de Pharmacie - 31 avenue Monge Tours - France. Equipe LNOx "Niche leucémique & métabolisme oxydatif" - GICC UMR 7292 CNRS - Université de Tours - Faculté de Médecine - Bâtiment Dutrochet - 10bis boulevard Tonnellé Tours - France. CHRU de Tours, Service d Hématologie Biologique, 2 boulevard Tonnellé Tours - France. * Corresponding author for chemistry part: gildas.prie@univ-tours.fr * Corresponding author for biological part: fabrice.gouilleux@univ-tours.fr Contents: S1 Compound 13 inhibition of STAT5 phosphorylation on KU812 cells 2 S2 KU812 cells proliferation with compounds 6a, 6b, 8, 13, 15a-c, 17a-f, 17i, 18 3 S3 K562 cells proliferation with compounds 6a, 6b, 8, 13, 15a-c, 17a-f, 17i, 18 4 S4 Apoptosis experiments with 17f in K562 and KU812 cells 5 S5 Dose-response curves for compounds 13, 14, 16, 17f, 17g, 17h on KU812 and K562 cells 6-8 S6 Dose-response curves for compounds 17f on KG1a and MV-4-11 cells 9 S7 KG1a cells proliferation with Rosiglitazone or 17f with or without GW S8 MV-4-11 cells proliferation with Rosiglitazone or 17f with or without GW S9 KU812 cells proliferation with Rosiglitazone or 17f with or without GW S10 Quantification of phosphorylation levels for STAT5, STAT3, Akt and Erk1/2 proteins 13 S11 Dose-response curves for compounds 17f on HS-27a and MSC cells 14 S H and 13 C NMR spectra of compounds

2 Figure S1. Compound 13 inhibition of STAT5 phosphorylation in KU812 cells. Protein extracts from KU812 cells treated or not with 13 (10 µm) for 72 hours were analyzed by Western blotting to detect STAT5 and P-Y- STAT5 protein expression (n = 2). 2

3 Figure S2. Growth of KU812 cells treated for 24, 48 or 72 hours with 10 µm of 6a, 6b, 8, 13, 15a-c, 17a-f, 17i, 18, or DMSO as control; Living cells were counted using trypan blue dye exclusion assays (n = 3 in triplicates, data are mean ± SEM). 3

4 Figure S3. Growth of K562 cells treated for 24, 48 or 72 hours with 10 µm of 6a, 6b, 8, 13, 15a-c, 17a-f, 17i, 18, or DMSO as control; Living cells were counted using trypan blue dye exclusion assays (n = 3 in triplicates, data are mean ± SEM). 4

5 Figure S4. Representative flow cytometry histogram of K562 and KU812 cells cultured for 48h with 17f compound (10µM) or control DMSO. Cells were stained with FITC-Annexin V and 7-AAD and the percentages of apoptotic cells were then evaluated by flow cytometry (n = 3 in triplicates, data are mean ± SEM, *p < 0.05). 5

6 6

7 7

8 Figure S5. EC 50 determination on K562 and KU812 cell lines with 13 (A), 14 (B), 16 (C), 17f (D), 17g (E), 17h (F); Cells were treated with different doses of selected molecules (ranging from 100 nm to 50 µm) for 48 hours; Viability evaluation by MTT assays; data acquisition using Clariostar 570 nm; viability = (DO Treated sample / DO Control sample) x 100; EC 50 calculation using logistic function on Origin software (n = 3 in triplicates, data are mean ± SEM). 8

9 Figure S6. EC 50 determination on KG1a and MV-4-11 cell lines with 17f; Cells were treated with different concentrations of 17f (100 nm to 50 µm) for 48 hours; Viability evaluation by MTT assays; data acquisition using Clariostar 570 nm; viability = (DO Treated sample / DO Control sample) x 100; EC 50 calculation using logistic function on Origin software (n = 3 in triplicates, data are mean ± SEM). 9

10 Figure S7. Growth of KG1a cells treated for 24, 48 or 72 hours with the PPARγ agonist Rosiglitazone (10 µm) or 17f (10 µm) with or without GW9662 (10 µm) or with DMSO as control. Alive cells were counted using trypan blue coloration (n = 3 in triplicates, data are mean ± SEM). 10

11 Figure S8. Growth of MV-4-11 cells treated for 24, 48 or 72 hours with the PPARγ agonist Rosiglitazone (10 µm) or 17f (10 µm) with or without GW9662 (10 µm) or with DMSO as control; alive cells were counted using trypan blue dye exclusion assays (n = 3 in triplicates, data are mean ± SEM). 11

12 Figure S9. Growth of KU812 cells treated for 24, 48 or 72 hours with the PPARγ agonist Rosiglitazone (10 µm) or 17f (10 µm) with or without GW9662 (10 µm) or with DMSO as control; alive cells were counted using trypan blue dye exclusion assays (n = 3 in triplicates, data are mean ± SEM). 12

13 Figure S10. The relative expression of phosphorylated STAT5, STAT3, Akt and Erk1/2 proteins in leukemia cells treated for 24 h with 17f or DMSO (control) were evaluated by band intensity quantification (n = 2). Each percentage has been calculated by dividing values obtained for phosphorylated proteins by the corresponding values obtained for total proteins, and then normalizing against actin (control). 13

14 Figure S11. EC 50 determination of 17f for HS-27a and MSC cells (3 patients Mesenchymal Stem Cells). Cells were treated with concentrations ranging from 1 µm to 100 µm for 48 hours; viability evaluation with MTT assays; data acquisition using Clariostar 570 nm; viability = (DO Treated sample / DO Control sample) x 100; EC 50 calculation using logistic function on Origin software (n = 3 in triplicates, data are mean ± SEM). 14

15 Figure S12. 1 H NMR (DMSO-d 6, 300 MHz) of 1 Figure S C NMR (DMSO-d 6, 75 MHz) of 1 15

16 Figure S14. 1 H NMR (DMSO-d 6, 300 MHz) of 2 Figure S C NMR (DMSO-d 6, 75 MHz) of 2 16

17 Figure S16. 1 H NMR (CDCl 3, 300 MHz) of 3 Figure S C NMR (CDCl 3, 75 MHz) of 3 17

18 Figure S18. 1 H NMR (CDCl 3, 300 MHz) of 4 Figure S C NMR (CDCl 3, 75 MHz) of 4 18

19 Figure S20. 1 H NMR (CDCl 3, 300 MHz) of 5 Figure S C NMR (CDCl 3, 75 MHz) of 5 19

20 Figure S22. 1 H NMR (CDCl 3, 300 MHz) of 6a Figure S C NMR (CDCl 3, 75 MHz) of 6a 20

21 Figure S24. 1 H NMR (DMSO-d 6, 300 MHz) of 6b Figure S C NMR (DMSO-d 6, 75 MHz) of 6b 21

22 Figure S26. 1 H NMR (DMSO-d 6, 300 MHz) of 7 Figure S C NMR (DMSO-d 6, 75 MHz) of 7 22

23 Figure S28. 1 H NMR (CDCl 3, 300 MHz) of 8 Figure S C NMR (CDCl 3, 75 MHz) of 8 23

24 Figure S30. 1 H NMR (DMSO-d 6, 300 MHz) of 9 Figure S C NMR (DMSO-d 6, 75 MHz) of 9 24

25 Figure S32. 1 H NMR (DMSO-d 6, 300 MHz) of 10 Figure S C NMR (DMSO-d 6, 75 MHz) of 10 25

26 Figure S34. 1 H NMR (DMSO-d 6, 300 MHz) of 11 Figure S C NMR (DMSO-d 6, 75 MHz) of 11 26

27 Figure S36. 1 H NMR (DMSO-d 6, 300 MHz) of 12 Figure S C NMR (DMSO-d 6, 75 MHz) of 12 27

28 Figure S38. 1 H NMR (DMSO-d 6, 300 MHz) of 13 Figure S C NMR (DMSO-d 6, 75 MHz) of 13 28

29 Figure S40. 1 H NMR (CDCl 3, 300 MHz) of 14 Figure S C NMR (CDCl 3, 75 MHz) of 14 29

30 Figure S42. 1 H NMR (CDCl 3, 300 MHz) of 15a Figure S C NMR (CDCl 3, 75 MHz) of 15a 30

31 Figure S44. 1 H NMR (DMSO-d 6, 300 MHz) of 15b Figure S C NMR (DMSO-d 6, 75 MHz) of 15b 31

32 Figure S46. 1 H NMR (DMSO-d 6, 300 MHz) of 15c Figure S C NMR (DMSO-d 6, 75 MHz) of 15c 32

33 Figure S48. 1 H NMR (CDCl 3, 300 MHz) of 16 Figure S C NMR (CDCl 3, 75 MHz) of 16 33

34 Figure S50. 1 H NMR (CDCl 3, 300 MHz) of 17a Figure S C NMR (CDCl 3, 75 MHz) of 17a 34

35 Figure S52. 1 H NMR (CDCl 3, 300 MHz) of 17b Figure S C NMR (CDCl 3, 75 MHz) of 17b 35

36 Figure S54. 1 H NMR (CDCl 3, 300 MHz) of 17c Figure S C NMR (CDCl 3, 75 MHz) of 17c 36

37 Figure S56. 1 H NMR (CDCl 3, 300 MHz) of 17d Figure S C NMR (CDCl 3, 75 MHz) of 17d 37

38 Figure S58. 1 H NMR (CDCl 3, 300 MHz) of 17e Figure S C NMR (CDCl 3, 75 MHz) of 17e 38

39 Figure S60. 1 H NMR (CDCl 3, 300 MHz) of 17f Figure S C NMR (CDCl 3, 75 MHz) of 17f 39

40 Figure S62. 1 H NMR (DMSO-d 6, 300 MHz) of 17g Figure S C NMR (DMSO-d 6, 75 MHz) of 17g 40

41 Figure S64. 1 H NMR (DMSO-d 6, 300 MHz) of 17h Figure S C NMR (DMSO-d 6, 75 MHz) of 17h 41

42 Figure S66. 1 H NMR (DMSO-d 6, 300 MHz) of 17i Figure S C NMR (DMSO-d 6, 75 MHz) of 17i 42

43 Figure S68. 1 H NMR (DMSO-d 6, 300 MHz) of 18 Figure S C NMR (DMSO-d 6, 75 MHz) of 18 43